CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease

NDA FilingALXN1840Positive
AI Analysis

Summary

Monopar Therapeutics has initiated a rolling application for ALXN1840 in Wilson Disease, indicating progression toward regulatory approval.

Importance:6/10
Sentiment:
0.60
regulatoryNDArolling submissionWilson Disease
Related Companies

Read the original article

Published by yahoo_finance on July 22, 2026 12:55 PM

Read Original